Drug Trial Radar · NCT00426660
Expanded Access Program for Maraviroc At Multiple Centers
Last checked: Nov 20, 2026Latest source record: Jun 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,047
Actual
Start
Feb 2007
Primary completion
Jun 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 25, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.
Conditions
- HIV Infections
Interventions
maravirocDrug
The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)Time frame: Baseline up to Week 144
- Percentage of Participants With Grade 3 Laboratory Abnormalities Without Regards to Baseline AbnormalitiesTime frame: Baseline up to Week 144
- Percentage of Participants With Grade 4 Laboratory Abnormalities Without Regards to Baseline AbnormalitiesTime frame: Baseline up to Week 144
- Percentage of Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining IllnessesTime frame: Baseline up to Week 144
- Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline Viral LoadTime frame: Baseline up to Week 144
- Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Baseline/Nadir CD4 Cell CountsTime frame: Baseline up to Week 144
- Percentage of Participants With Possible Acquired Immunodeficiency Syndrome (AIDS) Related Infections and Malignancies by Time on TherapyTime frame: Baseline up to Week 144
- Percentage of Participants With All Causality Treatment-emergent Adverse (AEs) Events by GenderTime frame: Baseline up to Week 144
- Percentage of Participants With Treatment-emergent Adverse Events (AEs) by RaceTime frame: Baseline up to Week 144
- Percentage of Participants With Treatment-emergent Adverse Events (AEs) by AgeTime frame: Baseline up to Week 144
- Percentage of Participants With Treatment-emergent Averse Events (AEs) by Baseline Hepatitis B and Hepatitis C Virus Serology StatusTime frame: Baseline up to Week 144
Locations
361 sites in 26 countries. Site status is shown where the registry gives one.
The University of Alabama
Birmingham, Alabama
Health Services Center
Hobson City, Alabama
El Rio, Special Immunology Associates
Tucson, Arizona
Health for Life Clinic PLLC
Little Rock, Arkansas
Thomas T Jefferson, MD
Little Rock, Arkansas
Vista Medical
Beverly Hills, California
AHF Research Center
Beverly Hills, California
Orange County Center for Special Immunology
Fountain Valley, California
Kaiser Permanente
Hayward, California
Living Hope Clinical Trials
Long Beach, California
AltaMed Health Services Corporation
Los Angeles, California
Kaiser Permanente Medical Center
Los Angeles, California
Robert Bolan, MD
Los Angeles, California
Maternal-Child and Adolescent Clinic of Infectious Diseases and Virology
Los Angeles, California
Peter J. Ruane, M.D. Inc.
Los Angeles, California
Synergy Hematology-Oncology Associates
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Erlmed Corp ABA Lim-Keith Muiltispecialty Clinic Inc.
Los Angeles, California
Office of Anthony Mills, MD
Los Angeles, California
Office of Dr. Salah Bibi, MD
Modesto, California
Bonnie V Bock MD
Newport Beach, California
Alta Bates Summit Medical Center
Oakland, California
Desert Medical Group, Clinical Research Center
Palm Springs, California
Riverside Medical Clinic
Riverside, California
Fort Sutter Medical Complex
Sacramento, California
Sutter Institute for Medical Research
Sacramento, California
Sutter Medical Group
Sacramento, California
Quest Clinical Research
San Francisco, California
Kaiser Permanente Medical Center
San Francisco, California
Kaiser Permanente Santa Clara
Santa Clara, California
Shared Medical Research Foundation
Tarzana, California
Tarzana Treatment Center
Tarzana, California
Bipin Bhagat MD Inc.
Victorville, California
Kaiser Permanente Colorado
Denver, Colorado
Kaiser Permanente of Colorado
Denver, Colorado
Denver Infectious Disease Consultants, PLLC
Denver, Colorado
Kaiser Permanente of Colorado
Lafayette, Colorado
Connecticut Health Care Group
Glastonbury, Connecticut
Infectious Disease Clinic
Norwich, Connecticut
Dupont Circle Physicians Group
Washington D.C., District of Columbia
Showing 40 of 361 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.